MBSB Announces Exclusive Worldwide Human Health Care License Rights to its External Wound Care Products FORT WORTH, TX -- (MARKET WIRE) 11/29/07 -- MB Software Corporation (OTCBB: MBSB) announced today that its wholly ow

MBSB Announces Exclusive Worldwide Human Health Care License

Rights to its External Wound Care Products

FORT WORTH, TX -- (MARKET WIRE) 11/29/07 -- MB Software

Corporation (OTCBB: MBSB) announced today that its wholly owned subsidiary Wound

Care Innovations LLC has entered into enhanced agreements with the licensors of

its wound care products under which the company now has the exclusive worldwide

license to market and sell the current products and any new developed products

for the human health care market for external wound care.

The company has been actively marketing the CellerateRx

brand of products within the United States to the human health care market and

foresees even greater growth with this development. "We are very pleased with

our enhanced agreements and believe they strengthen our ability to grow our

company faster as we now have the ability to offer our products to the rest of

the world," said Scott Haire, the company's Chairman. "These enhanced agreements

coupled with our recent announcement of evidence-based studies on the Cellerate

products will give us greater momentum going into 2008 and beyond."

The company's Vice president of Corporate Development, Cathy

Bradshaw further noted, "our current Cellerate products are FDA cleared for

marketing for all wounds except 3rd degree burns, and are effective in all wound

phases and states. CellerateRX is peerless in its simplicity of use and

application as an advanced therapy. It reduces the costs of wound care therapies

and is safe, biocompatible and biodegradable. It is important to note that our

product can be used with all other current wound care therapies. We continue to

have great results with the product and now we will expand our sales efforts to

the worldwide human health care arena."

CellerateRX is available in two forms, a powder and a gel,

and both products feature HCPCS codes for reimbursement in the USA.

About MB Software Corporation:

MB Software Corporation (OTCBB: MBSB), with its corporate

headquarters in Fort Worth, Texas, markets and distributes wound care products

to the healthcare market under patented technology licensed to the Company. The

Company is positioned and seeks to be a leading provider of wound care products.

For more information on the Company please visit the Company's Website at

www.CellerateRX.com .

"Safe Harbor" Statement: Under The Private Securities

Litigation Reform Act of 1995: The statements in the press release that relate

to the company's expectations with regard to the future impact on the company's

results from new products in development are "forward-looking statements,"

within the meaning of the Private Securities Litigation Reform Act of 1995.

Since this information may contain statements that involve risk and

uncertainties and are subject to change at any time, the company's actual

results may differ materially from expected results. This document may contain

forward-looking statements concerning the Company's operations, current and

future performance and financial condition. These items involve risks and

uncertainties such as product demand, market and customer acceptance, the effect

of economic conditions, competition, pricing, the ability to consummate and

integrate acquisitions, and other risks and uncertainties detailed in the

Company's SEC filings. The Company undertakes no obligation to revise any of

these statements to reflect the future circumstances or the occurrence of

unanticipated events.